TargetBeta
KRAS
KRas proto-oncogene, GTPase · also KRAS1, K-Ras4B, KRAS2 · RAS type GTPase family
41 programs in company-led studies act on KRAS, from 32 companies: 16 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (31 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 1211 running | – | NCIt |
| daraxonrasibrule | Revolution Medicines | phase 3 | 1010 running | HRAS, NRAS | NCIt |
| divarasib | Hoffmann-La Roche | phase 3 | 139 running | – | a judged reading |
| calderasib | Merck | phase 3 | 128 running | – | a judged reading |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 128 running | – | NCIt |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 167 running | – | NCIt |
| olomorasib | Eli Lilly | phase 3 | 167 running | – | a judged reading |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 77 running | – | the company's pipeline |
| sotorasibrule | Amgen | phase 3 | 286 running | – | NCIt |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 66 running | – | the company's pipeline |
| zoldonrasibrule | Revolution Medicines | phase 3 | 66 running | – | NCIt |
| garsorasibrule | InventisBio | phase 3 | 84 running | – | NCIt |
| KRAS G12D Inhibitor INCB161734rule | Incyte | phase 3 | 54 running | – | NCIt |
| opnurasibrule | Novartis | phase 3 | 53 running | – | NCIt |
| KRAS G12C Inhibitor JMKX001899rule | Jemincare | phase 3 | 33 running | – | NCIt |
| KRAS G12C Inhibitor HS-10370rule | Hansoh Pharmaceutical Group | phase 3 | 21 running | – | NCIt |
| KRAS G12D Inhibitor QLC1101rule | Qilu Pharmaceutical | phase 2 | 33 running | – | NCIt |
| Pan-KRAS Inhibitor JAB-23E73 | Jacobio Pharmaceuticals | phase 2 | 22 running | – | a judged reading |
| elisrasibrule | D3 Bio (Wuxi) | phase 2 | 21 running | – | NCIt |
| Pan-KRAS Inhibitor BLU-924 | Sanofi | phase 2 | 11 running | – | the company's pipeline |
| KRAS G12D Inhibitor KQB548rule | Bayer | phase 1 | 22 running | – | NCIt |
| AZD0240 | AstraZeneca | phase 1 | 11 running | – | a judged reading |
| HS-10529rule | Hansoh Pharmaceutical Group | phase 1 | 11 running | – | the studies' text |
| HS-10541 | Hansoh Pharmaceutical Group | phase 1 | 11 running | – | the company's pipeline |
| KRAS G12D Inhibitor INCB186748rule | Incyte | phase 1 | 11 running | – | NCIt |
| KRAS G12V Inhibitor RMC-5127rule | Revolution Medicines | phase 1 | 11 running | – | NCIt |
| KRAS Mutant Inhibitor ALTA3263rule | Alterome Therapeutics | phase 1 | 11 running | – | NCIt |
| KRAS Mutant Inhibitor BBO-11818rule | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | phase 1 | 11 running | – | NCIt |
| KRAS Mutant Inhibitor KQB365rule | Kumquat Biosciences | phase 1 | 11 running | – | NCIt |
| KRAS Mutant Inhibitor KQB368rule | Kumquat Biosciences | phase 1 | 11 running | – | NCIt |
| KRAS Mutant Inhibitor QTX3544rule | Quanta Therapeutics | phase 1 | 11 running | – | NCIt |
| LT-010391rule | Leadingtac Pharmaceutical (Shaoxing) | phase 1 | 11 running | – | the studies' text |
| NW-301Vrule | Neowise Biotechnology | phase 1 | 11 running | – | the studies' text |
| Pan-KRAS Degrader ASP5834rule | Astellas Pharma | phase 1 | 11 running | – | NCIt |
| Pan-KRAS Degrader PT0511rule | PAQ Therapeutics | phase 1 | 11 running | – | NCIt |
| Pan-KRAS Inhibitor AMG 410rule | Amgen | phase 1 | 11 running | – | NCIt |
| Pan-KRAS Inhibitor AUBE00 | Hoffmann-La Roche | phase 1 | 11 running | – | the company's pipeline |
| Pan-KRAS Inhibitor ERAS-4001rule | Erasca | phase 1 | 11 running | – | NCIt |
| Pan-KRAS Inhibitor TLN-372rule | Treeline Biosciences | phase 1 | 11 running | – | NCIt |
| RAS Inhibitor AN9025rule | Adlai Nortye Biopharma | phase 1 | 11 running | NRAS | NCIt |
| Pan-KRAS Inhibitor PF-07985045rule | Pfizer | phase 1 | 10 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 22 programs
- Colorectal Neoplasms, 12 programs
- Pancreatic Neoplasms, 8 programs
- Renal Insufficiency, 3 programs
- Hepatic Insufficiency, 2 programs
- Neoplasm Metastasis, 2 programs
- Neoplasms, 2 programs
- Adenocarcinoma of Lung, 1 program
- Appendiceal Neoplasms, 1 program
- Biliary Tract Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026divarasib · Hoffmann-La Roche · phase 3 · NCT04302025
- Dec 2026HRS-7058 · Jiangsu HengRui Medicine · phase 3 · NCT06915142
- Dec 17, 2026sotorasib · Amgen · phase 3 · NCT04185883
- Dec 31, 2026glecirasib · Allist Pharmaceuticals · phase 3 · NCT06008288
- Dec 31, 2026zoldonrasib · Revolution Medicines · phase 3 · NCT06040541
- Dec 31, 2026Pan-KRAS Inhibitor JAB-23E73 · Jacobio Pharmaceuticals · phase 2 · NCT06959615
- Jan 1, 2027KRAS G12D Inhibitor INCB161734 · Incyte · phase 3 · NCT06179160
- Jan 2, 2027KRAS Mutant Inhibitor QTX3544 · Quanta Therapeutics · phase 1 · NCT06715124
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.